{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:12:34Z","timestamp":1778803954287,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jtct.2022.09.024","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T02:35:36Z","timestamp":1664850936000},"page":"55.e1-55.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study"],"prefix":"10.1016","volume":"29","author":[{"given":"Yaeni","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-3991","authenticated-orcid":false,"given":"Seung-Ah","family":"Yahng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hwan","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.09.024_bib0001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PPO.0000000000000348","article-title":"Optimizing immunomodulatory drug with proteasome inhibitor combinations in newly diagnosed multiple myeloma","volume":"25","author":"Ntanasis-Stathopoulos","year":"2019","journal-title":"Cancer J"},{"key":"10.1016\/j.jtct.2022.09.024_bib0002","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.5045\/br.2020.S007","article-title":"Frontline therapy for newly diagnosed patients with multiple myeloma","volume":"55","author":"Jung","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.jtct.2022.09.024_bib0003","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.5045\/br.2020.S008","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"55","author":"Lee","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.jtct.2022.09.024_bib0004","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.09.024_bib0005","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.09.024_bib0006","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.09.024_bib0007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nrneph.2011.168","article-title":"The pathogenesis and diagnosis of acute kidney injury in multiple myeloma","volume":"8","author":"Hutchison","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jtct.2022.09.024_bib0008","first-page":"207","article-title":"Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival","volume":"56","author":"Abbott","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jtct.2022.09.024_bib0009","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0277-5379(91)90020-E","article-title":"Changing clinical presentation of multiple myeloma","volume":"27","author":"Riccardi","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtct.2022.09.024_bib0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/ndt\/gfp679","article-title":"Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study","volume":"25","author":"Tsakiris","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jtct.2022.09.024_bib0011","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2022.09.024_bib0012","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/ejh.12644","article-title":"Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury","volume":"96","author":"Yadav","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2022.09.024_bib0013","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.transproceed.2020.02.067","article-title":"Negative impact of borderline creatinine concentration and glomerular filtration rate at baseline on the outcome of patients with multiple myeloma treated with autologous stem cell transplant","volume":"52","author":"Waszczuk-Gajda","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jtct.2022.09.024_bib0014","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2022.09.024_bib0015","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.20.00298","article-title":"Randomized trial comparing double versus triple bortezomib-based regimens in patients with multiple myeloma and acute kidney injury due to cast nephropathy","volume":"38","author":"Bridoux","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.09.024_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9401717","article-title":"Autologous stem cell transplantation in multiple myeloma with renal failure: friend or foe?","volume":"2019","author":"Zhong","year":"2019","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.jtct.2022.09.024_bib0017","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.09.024_bib0018","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.09.024_bib0019","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/cancers13061322","article-title":"Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM","volume":"13","author":"Bachmann","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2022.09.024_bib0020","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1002\/cam4.3050","article-title":"Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma","volume":"9","author":"Kobayashi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2022.09.024_bib0021","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","article-title":"The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.09.024_bib0022","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtct.2022.09.024_bib0023","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.ajkd.2015.10.019","article-title":"Acute kidney injury recovery pattern and subsequent risk of CKD: an analysis of Veterans Health Administration data","volume":"67","author":"Heung","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jtct.2022.09.024_bib0024","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00134-017-4809-x","article-title":"Renal recovery after acute kidney injury","volume":"43","author":"Forni","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jtct.2022.09.024_bib0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.09.024_bib0026","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3904\/kjm.2014.86.2.190","article-title":"Risk factors and reversibility of renal failure in patients with newly diagnosed multiple myeloma","volume":"86","author":"Whang","year":"2014","journal-title":"Korean J Med"},{"key":"10.1016\/j.jtct.2022.09.024_bib0027","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1182\/bloodadvances.2020002872","article-title":"Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial","volume":"4","author":"Rana","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.09.024_bib0028","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-018-0122-8","article-title":"Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC","volume":"53","author":"Augeul-Meunier","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.024_bib0029","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/bmt.2013.109","article-title":"Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT","volume":"48","author":"Glavey","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.09.024_bib0030","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.leu.2401819","article-title":"Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure","volume":"14","author":"Tosi","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.09.024_bib0031","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.24335","article-title":"Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis","volume":"91","author":"Dimopoulos","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.09.024_bib0032","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41409-019-0697-8","article-title":"Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras","volume":"55","author":"Li","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722016657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722016657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:23Z","timestamp":1763003363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722016657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2666636722016657"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.09.024","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}